Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2012 3
2013 1
2014 6
2015 8
2016 10
2017 15
2018 16
2019 16
2020 8
2021 8
2022 7
2023 3
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

91 results

Results by year

Filters applied: . Clear all
Page 1
Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection (GS-US-380-1489): a double-blind, multicentre, phase 3, randomised controlled non-inferiority trial.
Gallant J, Lazzarin A, Mills A, Orkin C, Podzamczer D, Tebas P, Girard PM, Brar I, Daar ES, Wohl D, Rockstroh J, Wei X, Custodio J, White K, Martin H, Cheng A, Quirk E. Gallant J, et al. Lancet. 2017 Nov 4;390(10107):2063-2072. doi: 10.1016/S0140-6736(17)32299-7. Epub 2017 Aug 31. Lancet. 2017. PMID: 28867497 Clinical Trial.
Bictegravir is a novel, potent INSTI with a high in-vitro barrier to resistance and low potential as a perpetrator or victim of clinically relevant drug-drug interactions. We aimed to assess the efficacy and safety of bictegravir coformulated with emtricitabine and …
Bictegravir is a novel, potent INSTI with a high in-vitro barrier to resistance and low potential as a perpetrator or victim of clinically r …
An up-to-date evaluation of dolutegravir/abacavir/lamivudine for the treatment of HIV.
Christensen BL, Tan DH. Christensen BL, et al. Expert Opin Pharmacother. 2022 Mar;23(4):439-446. doi: 10.1080/14656566.2022.2029409. Epub 2022 Jan 24. Expert Opin Pharmacother. 2022. PMID: 35073817 Review.
INTRODUCTION: There are more than 30 agents available for the treatment of HIV with guidelines shifting toward integrase strand transfer inhibitors (INSTIs) as part of first line therapy. The fixed dose combination of dolutegravir (DTG), abacavir (ABC), and lamiv
INTRODUCTION: There are more than 30 agents available for the treatment of HIV with guidelines shifting toward integrase strand transfer inh …
Major revision version 11.0 of the European AIDS Clinical Society Guidelines 2021.
Ryom L, De Miguel R, Cotter AG, Podlekareva D, Beguelin C, Waalewijn H, Arribas JR, Mallon PWG, Marzolini C, Kirk O, Bamford A, Rauch A, Molina JM, Kowalska JD, Guaraldi G, Winston A, Boesecke C, Cinque P, Welch S, Collins S, Behrens GMN; EACS Governing Board. Ryom L, et al. HIV Med. 2022 Sep;23(8):849-858. doi: 10.1111/hiv.13268. Epub 2022 Mar 25. HIV Med. 2022. PMID: 35338549 Free PMC article.
KEY POINTS OF THE GUIDELINES UPDATE: Version 11.0 of the Guidelines recommend six first-line treatment options for antiretroviral treatment (ART)-naive adults: tenofovir-based backbone plus an unboosted integrase inhibitor or plus doravirine; abacavir/lamivudine plu …
KEY POINTS OF THE GUIDELINES UPDATE: Version 11.0 of the Guidelines recommend six first-line treatment options for antiretroviral treatment …
Dolutegravir, abacavir and lamivudine as HIV therapy.
Fernandez-Montero JV, Barreiro P, Labarga P, De Mendoza C, Soriano V. Fernandez-Montero JV, et al. Expert Opin Pharmacother. 2014 May;15(7):1051-7. doi: 10.1517/14656566.2014.913023. Expert Opin Pharmacother. 2014. PMID: 24754315 Review.
INTRODUCTION: Antiretroviral therapy has evolved dramatically and more potent, safer and convenient drugs have replaced former compounds. Dolutegravir (DTG) is the most recently approved integrase inhibitor. ...Moreover, it is planned to be marketed, co-formulated with …
INTRODUCTION: Antiretroviral therapy has evolved dramatically and more potent, safer and convenient drugs have replaced former compounds. …
Abacavir/dolutegravir/lamivudine single-tablet regimen: a review of its use in HIV-1 infection.
Greig SL, Deeks ED. Greig SL, et al. Drugs. 2015 Apr;75(5):503-14. doi: 10.1007/s40265-015-0361-6. Drugs. 2015. PMID: 25698454 Review.
A fixed-dose, single-tablet regimen comprising the integrase strand transfer inhibitor (INSTI) dolutegravir and the nucleos(t)ide reverse transcriptase inhibitors (NRTIs) abacavir and lamivudine (abacavir/dolutegravir/lamivudine; Triumeq) …
A fixed-dose, single-tablet regimen comprising the integrase strand transfer inhibitor (INSTI) dolutegravir and the nucleos(t)ide rev …
Abacavir + dolutegravir + lamivudine for the treatment of HIV.
Comi L, Maggiolo F. Comi L, et al. Expert Opin Pharmacother. 2016 Oct;17(15):2097-106. doi: 10.1080/14656566.2016.1232387. Epub 2016 Sep 13. Expert Opin Pharmacother. 2016. PMID: 27616133 Review.
INTRODUCTION: Since the last revision of both European and American guidelines (EACS and DHHS), new data from clinical trials and cohort studies, as well as experience in clinical practice, have prompted significant changes to the list of recommended/preferred options for the tre …
INTRODUCTION: Since the last revision of both European and American guidelines (EACS and DHHS), new data from clinical trials and cohort stu …
Fixed-dose combination bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir-containing regimens for initial treatment of HIV-1 infection: week 144 results from two randomised, double-blind, multicentre, phase 3, non-inferiority trials.
Orkin C, DeJesus E, Sax PE, Arribas JR, Gupta SK, Martorell C, Stephens JL, Stellbrink HJ, Wohl D, Maggiolo F, Thompson MA, Podzamczer D, Hagins D, Flamm JA, Brinson C, Clarke A, Huang H, Acosta R, Brainard DM, Collins SE, Martin H; GS-US-380-1489; GS-US-380-1490 study investigators. Orkin C, et al. Lancet HIV. 2020 Jun;7(6):e389-e400. doi: 10.1016/S2352-3018(20)30099-0. Lancet HIV. 2020. PMID: 32504574 Clinical Trial.
FINDINGS: 629 participants were randomly assigned and treated in study 1 (314 to bictegravir, emtricitabine, and tenofovir alafenamide, and 315 to dolutegravir, abacavir, and lamivudine) and 645 in study 2 (327 to bictegravir, emtricitabine, and tenofovir ala …
FINDINGS: 629 participants were randomly assigned and treated in study 1 (314 to bictegravir, emtricitabine, and tenofovir alafenamide, and …
Single tablet regimen with abacavir/lamivudine/dolutegravir compared with two-drug regimen with lamivudine and dolutegravir as different strategies of simplification from a multicenter HIV cohort study.
Baldin G, Ciccullo A, Rusconi S, Madeddu G, Sterrantino G, Freedman A, Giacometti A, Celani L, Latini A, Rossetti B, Cossu MV, Giacomelli A, Lagi F, Capetti A, Di Giambenedetto S. Baldin G, et al. Infez Med. 2019 Dec 1;27(4):410-414. Infez Med. 2019. PMID: 31846991 Free article.
We investigated the effectiveness and safety of a dual therapy (DT) with lamivudine plus dolutegravir versus a single tablet regimen (STR) with abacavir/lamivudine/dolutegravir. We performed a retrospective analysis in a cohort of virologically …
We investigated the effectiveness and safety of a dual therapy (DT) with lamivudine plus dolutegravir versus a single tablet r …
Cost-effectiveness of dolutegravir/abacavir/lamivudine in HIV-1 treatment-Naive (TN) patients in France.
Pialoux G, Marcelin AG, Cawston H, Guilmet C, Finkielsztejn L, Laurisse A, Aubin C. Pialoux G, et al. Expert Rev Pharmacoecon Outcomes Res. 2018 Feb;18(1):83-91. doi: 10.1080/14737167.2017.1359542. Epub 2017 Jul 31. Expert Rev Pharmacoecon Outcomes Res. 2018. PMID: 28741965
BACKGROUND: To evaluate the cost-effectiveness of an integrase inhibitor (INI), dolutegravir (DTG), in combination with abacavir (ABC)/lamivudine (3TC) in France, in treatment-naive (TN) HIV adult patients. ...
BACKGROUND: To evaluate the cost-effectiveness of an integrase inhibitor (INI), dolutegravir (DTG), in combination with abacavir
91 results